UNSPSC 51392222: Fenoxazoline hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C13H18N2O.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6K28Y098S7. European Medicines Agency schedules fenoxazoline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02122MIG. The term fenoxazoline hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule fenoxazoline hydrochloride under HS 29332990 and SITC 51573.

As of Q4 2014, FENOXAZOLINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Fenoxazoline hydrochloride bears US NLM identifiers UMLS ID C0771654 and NCI Concept Code C65661. SMILES: CC(C)C1CCCCC1OCC2=NCCN2.CL.

UNSPSC 51392222 Fenoxazoline hydrochloride is a Commodity code tracking pharmaceutical compounds used in state and local health and emergency-response procurement, though recent activity shows significant mismatch between the code's nominal scope and actual solicitations. The code appears in state and local systems tagged to naloxone procurement and therapeutic pharmacy initiatives, with Seminole County, Florida and the Texas Health and Human Services Commission among recent issuers. State and local governments use this code family to procure emergency pharmaceuticals, overdose-reversal medications, drug deactivation systems, and direct-to-manufacturer prescription fulfillment arrangements as part of community health, public health, and employee benefits administration.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with response due July 26, 2023 (note: the date discrepancy in the source suggests administrative processing lag or data quality issue). The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, as a preliminary market-intelligence solicitation regarding direct-to-manufacturer prescription programs for a Therapeutic Pharmacy Initiative, with no formal bid deadline or award value specified at that information-gathering phase. Geographic activity centers on Florida and Texas, with procurement spanning county health departments and state health and human services agencies. The code shows limited recent activity relative to broader pharmaceutical procurement, and the disconnect between fenoxazoline hydrochloride (the nominal compound) and naloxone or direct-to-manufacturer prescription services (the actual buys) suggests either tagging inconsistency in state and local systems or that this Commodity code does not align with current market demand.